Eliana Merle
Stock Analyst at UBS
(2.19)
# 2,706
Out of 4,869 analysts
83
Total ratings
38.71%
Success rate
-1.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Maintains: Neutral | $16 → $8 | $7.36 | +8.70% | 3 | May 22, 2025 | |
| ARVN Arvinas | Maintains: Buy | $74 → $21 | $7.44 | +182.26% | 4 | May 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $72 → $70 | $45.87 | +52.61% | 3 | May 13, 2025 | |
| MRNA Moderna | Maintains: Buy | $78 → $70 | $25.90 | +170.27% | 7 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $441 → $458 | $285.73 | +60.29% | 4 | May 2, 2025 | |
| CVAC CureVac | Maintains: Buy | $13 → $12 | $5.44 | +120.79% | 2 | Apr 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $65 → $72 | $41.73 | +72.54% | 3 | Apr 30, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Overweight | $44 | $17.69 | +148.73% | 8 | Apr 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $55.00 | +105.45% | 2 | Feb 20, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $10.08 | +276.98% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $54.20 | +101.11% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.30 | +69.88% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $39.66 | +79.02% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $196 | $176.47 | +11.07% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $9.23 | +203.36% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $8.72 | +37.61% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $3.39 | -11.50% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.03 | +269.84% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $23.17 | +42.43% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $106.53 | +22.97% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $309.70 | -7.01% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.61 | +38.50% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $3.90 | +361.54% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $14.21 | +195.57% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.44 | +455.56% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.63 | +375.16% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.43 | +457.53% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.64 | +183.69% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $27.43 | +388.52% | 3 | Aug 19, 2020 |
RAPT Therapeutics
May 22, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $7.36
Upside: +8.70%
Arvinas
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $7.44
Upside: +182.26%
Kymera Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $45.87
Upside: +52.61%
Moderna
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $25.90
Upside: +170.27%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $441 → $458
Current: $285.73
Upside: +60.29%
CureVac
Apr 30, 2025
Maintains: Buy
Price Target: $13 → $12
Current: $5.44
Upside: +120.79%
BridgeBio Pharma
Apr 30, 2025
Maintains: Buy
Price Target: $65 → $72
Current: $41.73
Upside: +72.54%
Apellis Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $17.69
Upside: +148.73%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $55.00
Upside: +105.45%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $10.08
Upside: +276.98%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $54.20
Upside: +101.11%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.30
Upside: +69.88%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $39.66
Upside: +79.02%
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $176.47
Upside: +11.07%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $9.23
Upside: +203.36%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $8.72
Upside: +37.61%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $3.39
Upside: -11.50%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $7.03
Upside: +269.84%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $23.17
Upside: +42.43%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $106.53
Upside: +22.97%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $309.70
Upside: -7.01%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.61
Upside: +38.50%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $3.90
Upside: +361.54%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $14.21
Upside: +195.57%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.44
Upside: +455.56%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.63
Upside: +375.16%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.43
Upside: +457.53%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $5.64
Upside: +183.69%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $27.43
Upside: +388.52%